Detection of p53 Gene Mutations in the Supernatant of Pancreatic Juice and Plasma from Patients with Pancreatic Carcinomas

Wang, Ying; Yamaguchi, Yasushi; Watanabe, Hiroyuki; Ohtsubo, K.; Motoo, Yoshiharu; Sawabu, Norio

doi:10.1097/00006676-200401000-00002

Cited by 33 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Details of the analysis and complete data sets are available as part of the Supplementary Data. 8 The nylon array data set was filtered to include only featfures (genes) for which normalized intensities exceeded a value of 0.8 in at least 10 samples to remove uniformly low (and thus uninformative) signals. Control spots were excluded as well.…”

Section: Methodsmentioning

confidence: 99%

“…6). Based on these observations, several attempts have been made to improve the accuracy of preoperative diagnostics by analyzing molecular markers in pancreatic juice (7,8), brush cytologies (7,9), or FNAB's (10 -(10 -12) by means of RNA, DNA, or protein analysis. Most of these studies were aimed at detecting mutant K-ras in the biopsy samples because this is the gene most frequently affected by mutations (>85% of cases) in pancreatic ductal adenocarcinoma.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Specialized DNA Arrays for the Differentiation of Pancreatic Tumors

Buchholz¹,

Kestler

Bauer

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Malignant tumors of the pancreas are frequently indistinguishable from inflammatory tumors arising in the context of a chronic pancreatitis with the use of conventional imaging techniques. Thus, cytologic analysis of cells obtained by abdominal ultrasound, computed tomography, or endoscopic ultrasound^guided fine needle aspiration biopsy is required for diagnosis. However, the reliability of cytologic analyses of pancreatic fine needle aspirates remains unsatisfactory, with a diagnostic accuracy of V80%. The purpose of the current study was therefore to develop a novel diagnostic approach based on expression profiling of biopsy material using a specialized diagnostic cDNA array. Experimental Design: Previous gene expression profiling studies were reevaluated to design a 558-feature diagnostic array. Minimal amounts of residual material from pancreatic cytology samples as well as surgically resected tumor and control tissue specimens were analyzed using the diagnostic array and a newly developed statistical classification system. Results and Conclusions: Our diagnostic approach resulted in 95% accurate differentiation between ductal adenocarcinomas and nonmalignant tumors of the pancreas.The diagnostic array, in conjunction with conventional diagnostic procedures, is thus suitable to significantly improve the reliability of pancreatic cancer diagnostics and can be expected to become a valuable new tool in the routine workup of suspect masses in the pancreas.Pancreatic cancer is the fifth leading cause of cancer-related deaths in industrialized countries. With a 5-year survival rate of <5% and a median survival of <6 months, pancreatic cancer carries the most dismal prognosis of all solid tumors.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Specialized DNA Arrays for the Differentiation of Pancreatic Tumors

Buchholz¹,

Kestler

Bauer

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Once metastatic cells settle in a distant organ, nutrients and spaces are no longer www.wjgnet.com limited because newly formed metastases arise as islets of cancer cells surrounded by normal host cells. Invasion and metastasis are complex processes that involve molecular mechanisms, which lead to multiple gene alterations in pancreatic carcinoma, including alterations to KAI1, K-ras, DPC4 and P53 [3][4][5][6] . KAI1 was originally identified as a metastasis suppressor gene.…”

Section: Introductionmentioning

confidence: 99%

KAI1 is a potential target for anti-metastasis in pancreatic cancer cells

Guo²,

Ren³

et al. 2008

WJG

View full text Add to dashboard Cite

In vivo tumor growth rates of KAI1 transfectants with KAI1-Lipofectamine 1.22 ± 0.31 in A group were lower than control 4.61 ± 1.98 and pCMV-KAI 11.67 ± 0.81. Analyses of metastases with and without KAI1 transfection in mice were different in liver and lung between controls 1.62 ± 0.39, 0.45 ± 0.09, pCMV-KAI 1.01 ± 0.27, 0.33 ± 0.09 and KAI1-Lipofectamine 0.99 ± 0.21, 0.30 ± 0.09 respectively (P < 0.05). K e y w o r d s : K A I 1 ; P a n c r e a t i c c a n c e r c e l l l i n e ; Transfection; Immunocytochemistry; Western blotting; Immunofluorescence; Gelatinolysis CONCLUSION: INTRODUCTIONInvasion and metastasis are remarkable characteristics in pancreatic cancer. During invasion and metastasis, primary pancreatic cancer cells have to move out, invade adjacent tissue, and circulate to distant organs where they may form new colonies [1] . Tumor invasion encompasses the process of tumor cell penetration or infiltration into adjacent tissue; therefore, metastasis depends on host immunological ability, local and systemic expansion of the tumor mass, and angiogenesis [2] . Once metastatic cells settle in a distant organ, nutrients and spaces are no longer Abstract AIM: To investigate whether KAI1, as a metastasis suppressor gene, is associated with invasive and metastatic ability of pancreatic cancer cells. METHODS:KAI1 gene was transfected into pancreatic cancer cell line MiaPaCa Ⅱ by liposomes selected w i t h G 4 1 8 . E x p r e s s i o n o f t ra n s fe c t e d c e l l s wa s measured by Western blotting, immunofluorescence and immunocytochemistry. Tumor cell invasion and metastatic ability were detected through gelatinase a c t i v i ty a n d re c o n s t i t u t e d b a s e m e n t m e m b ra n e (Matrigel) assay.

show abstract

“…Мутации в гене p53 часто выявляются в цирДНК крови больных немелкоклеточным (30%) [135] и мелкоклеточным (37%) [136] раком лёгкого, раком яичника (15%) [137], желудка (5-12%) [138,139], у 19% больных раком поджелудочной железы [140], у 6%-21% больных раком кишечника [141,142] и у 18%-40% больных раком печени [143,144]. У больных раком кишечника наличие мутаций в этом гене коррелирует со стадией заболевания и метастазами в печень [141], а у больных раком молочной железы -со стадией заболевания, размером опухоли и метастазами в лимфатические узлы [145].…”

Section: особенности строения внеклеточных днк кровиunclassified

Generation of blood circulating DNA: the sources, peculiarities of circulation and structure

Bryzgunova

Laktionov

2015

BIOMED KHIM

View full text Add to dashboard Cite

Внеклеточные нуклеиновые кислоты (внНК) в циркуляции как здоровых, так и больных людей были впервые описаны в 1948 г., однако оставались без внимания до середины 60-х годов прошлого века. внНК особенно интенсивно исследуются в последние 5 лет. Основное внимание уделяется исследованию внНК как источнику диагностического материала; однако механизмы генерации внеклеточных нуклеиновых кислот, а также механизмы, обеспечивающие их долговременную циркуляцию в кровотоке, однозначно не установлены. По данным одних авторов, основным источником циркулирующих дезоксирибонуклеиновых кислот в крови (цирДНК) являются процессы некроза и апоптоза, другие ссылаются на возможную секрецию нуклеиновых кислот как здоровыми, так и опухолевыми клетками. Известно, что цирДНК могут циркулировать в крови в течение длительного времени, ускользая от действия ДНК-гидролизующих ферментов крови и, по-видимому, находясь в составе надмолекулярных комплексов. В этом обзоре представлены данные разных авторов и приведены доказательства в пользу всех предложенных теорий появления цирДНК, описаны особенности строения цирДНК, а также факторы, влияющие на время циркуляции ДНК в крови.Ключевые слова: циркулирующая ДНК, апоптоз, некроз, активная секреция, ДНКазы, метилирование.

show abstract

Detection of p53 Gene Mutations in the Supernatant of Pancreatic Juice and Plasma from Patients with Pancreatic Carcinomas

Abstract: These results suggest that the sensitivity of detection for p53 mutations with high cancer specificity could be improved by using the Sup in PPJ samples of PCa. Genetic analysis of p53 could complement PPJ cytology. p53 mutations were detectable in PCa from plasma samples.

Cited by 33 publications

References 24 publications

Specialized DNA Arrays for the Differentiation of Pancreatic Tumors

Specialized DNA Arrays for the Differentiation of Pancreatic Tumors

KAI1 is a potential target for anti-metastasis in pancreatic cancer cells

Generation of blood circulating DNA: the sources, peculiarities of circulation and structure

Contact Info

Product

Resources

About